From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through the Company’s unparalleled sensitivity and flexibility. Its industry-leading Simoa® precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding, management and patient care in neurology, oncology, immunology, cardiology and infectious disease for nearly two decades.